Carglumic Acid Market Size & Share 2026-2035

Carglumic Acid Market Size

The global carglumic acid market was estimated at USD 175 million in 2025. The market is expected to grow from USD 188.7 million in 2026 to USD 341.6 million in 2035, at a CAGR of 6.8% during the forecast period, according to the latest report published by Global Market Insights Inc.

Growing newborn screening programs, advancements in genetic testing technologies, and expansion into emerging markets are expected to fuel the industry's growth. Recordati Rare Diseases Inc., Dipharma, Apothecon Pharmaceuticals, and Biophore India Pharmaceuticals are among the leading players operating in the market. These players mainly focus on product innovation, geographic expansion, research on advanced formulations, strong R&D, and collaboration with local or regional healthcare providers, among other factors.
 

The market has increased from USD 134.9 million in 2022 and reached USD 161.6 million in 2024, with a historic growth rate of 9.5%. The rising incidences of metabolic diseases globally, including metabolic syndrome, type 2 diabetes mellitus, hypertension, and non-alcoholic fatty liver disease (NAFLD), are a growing concern, with significant increases observed in prevalence rates over the years. According to the Centers for Disease Control and Prevention (CDC), nearly half of adults in the U.S. have hypertension, affecting an estimated 119.9 million adults.
 

Additionally, the World Health Organization (WHO) emphasizes the importance of early diagnosis through regular check-ups and blood tests to prevent the worst effects of type 2 diabetes. This rise in the prevalence of such metabolic conditions is anticipated as a key factor contributing to the growth of the market.
 

Further, NAGS deficiency causes severe hyperammonemia due to the body’s inability to detoxify ammonia, leading to neurological damage, coma, or death when untreated. The treatment of carglumic acid corrects the CPS1 enzymatic reaction, allowing ammonia to be removed from the blood; therefore, it is critically important in a patient with NAGS deficiency. The overall awareness of NAGS deficiency is high, and diagnostic capabilities are improving; therefore, more patients with NAGS deficiency are being diagnosed early and will require effective products.
 

Carglumic acid is a medication used for the treatment of hyperammonemia, a condition characterized by elevated levels of ammonia in the blood. Hyperammonemia can be caused by various metabolic disorders, including urea cycle disorders. Carglumic acid works by promoting the excretion of ammonia in the urine, thereby reducing its concentration in the blood.
 

Carglumic Acid Market Trends

The rise in awareness coupled with surging research and development (R&D) activities by key industry players is crucial in addressing metabolic diseases. Industry organizations are actively involved in the development of treatments and solutions for metabolic disorders.
 

• The manufacturing key industry players have been actively engaged in surging research and development (R&D) activities to advance treatments and solutions for metabolic disorders. For instance, Eton Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. commercially launched Carglumic Acid tablets in December 2021, marking the first US FDA-approved generic version of this medication. Such activities are increasing the awareness of carglumic acid treatment among people and ultimately propelling their demand.
   
• Additionally, Recordati Rare Diseases Inc. received approval from the U.S. FDA for a new indication of CARBAGLU (carglumic acid) tablets 200mg as adjunctive therapy in January 2021. These initiatives highlight the commitment of industry leaders to drive innovation and improve therapeutic options for individuals affected by metabolic disorders like N-acetylglutamate Synthase (NAGS) Syndrome and anticipates propelling the market growth.
   

Carglumic Acid Market Analysis

Based on dosage form, the global carglumic acid market is segmented into orally disintegrating tablets, dispersible tablets and other dosage forms. The dispersible tablets segment accounted for a majority share of 58% in 2025. Improved access to rare disease therapies through reimbursement policies is anticipated to fuel the segmental growth. The segment is expected to reach USD 201.8 million by 2035, growing at a CAGR of 7% during the forecast period.
 

• Dispersible tablets offer convenience for patients who may have difficulty swallowing traditional tablets or capsules. This ease of administration, even for pediatric and geriatric patients, can lead to better patient adherence to treatment regimens.
   
• Moreover, with an increasing focus on patient-centric healthcare and the rising prevalence of conditions requiring carglumic acid treatment, there is a growing demand for convenient dosage forms such as dispersible tablets due to their convenient dosing features.
   
• The orally disintegrating tablets segment was valued at USD 50.4 million in 2025. Orally disintegrating tablets (ODTs) of carglumic acid play an increasingly important role in improving patient adherence, especially among infants, children, and individuals with swallowing difficulties.
   
• Additionally, ODTs are dissolved in water and can be taken immediately before meals, providing for accurate dosing and consistent metabolic control.
   
• Further, new formulations of the ODTs, as well as the dispersible tablets, have been designed to improve patient access and ease of use for both acute and chronic hyperammonemic conditions.

Based on distribution channel, the carglumic acid market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominates the market with the revenue of around USD 90.3 million in 2025.
 

• Hospital pharmacies are equipped to handle the distribution of medications for complex conditions such as hyperammonemia, ensuring that patients receive the necessary treatment in a timely manner, making them a major distribution channel of carglumic acid.
   
• Moreover, hospital pharmacies are staffed with pharmacists and healthcare professionals who have expertise in managing complex medication regimens and monitoring for potential drug interactions or adverse effects. This ensures safe and effective administration of carglumic acid to patients.
   
• The retail pharmacies segment is anticipated to reach over USD 110 million by 2035. Retail pharmacies serve as an important distribution channel for carglumic acid, complementing hospital and specialty pharmacy access. As patients with metabolic disorders and chronic hyperammonemia have increased, so has the importance of retail pharmacy as a means of accessing carglumic acid.
   
• In addition, retail pharmacies support patient access by providing availability in the community, assistance to patients through education and counseling, and providing refills for a family member with long-term disorders, including NAGS deficiency, PA, and MMA, and make the drug readily available at all times.
   
• Since carglumic acid is critical to the effective management of ammonia levels, improving access via retail pharmacies provides for consistent dosing and allows a quick start of treatment once the patient begins to show symptoms.
  

North America Carglumic Acid Market

The North America carglumic acid market accounted for a majority share of 40.4% in 2025 and is anticipated to show notable growth over the forecast period.
 

• The U.S. carglumic acid market was valued at USD 51.9 million and USD 56.9 million in 2022 and 2023, respectively. In 2025 the market size was valued at USD 66.5 million, up from USD 61.7 million in 2024.
   
• The rising healthcare expenditure in North America, coupled with a growing emphasis on specialty care and rare disease treatment, creates a conducive environment for the growth of medications like carglumic acid. Healthcare systems' willingness to invest in innovative therapies for rare conditions is anticipated to drive the uptake of carglumic acid in the region.
   
• Furthermore, the increasing prevalence of cancer in North America is indeed a significant factor that could indirectly impact the growth of carglumic acid usage. Certain cancers may lead to hyperammonemia as a complication, contributing to its rising prevalence in the region and ultimately anticipating the growing demand for the market in the region.
   

Europe Carglumic Acid Market

Europe accounted for a significant share of the global carglumic acid market and was valued at USD 50.3 million in 2025.
 

• The carglumic acid market is experiencing robust growth in Europe as a result of an established health care system and high metabolic disorder diagnostic rate.
   
• Europe remains one of the major markets globally due to its high level of clinical awareness and the presence of many specialized metabolic care centers.
   
• With its structured rare disease frameworks and early adoption of new therapies, including orally disintegrating and suspension formulations, it is likely that patients who are suffering from NAGS deficiency, PA, and MMA will have greater access to treatment.
   
• Furthermore, continued product development and increased regulatory activity, including revised EMA documentation for carbaglu, are ensuring consistency in clinical guidance and safe usage. Therefore, the above variables continue to propel the demand for carglumic acid throughout different European countries.
   

Asia Pacific Carglumic Acid Market

The Asia Pacific carglumic acid market accounted for a substantial share of the market and was valued at USD 40.4 million in 2025.
 

• The carglumic acid market within the Asia Pacific region is experiencing rapid growth, which can be attributed to several factors, including the accelerating pharmaceutical development capabilities of regional countries, a growing awareness of metabolic disorders, and an increasing number of patients diagnosed with hyperammonemia and related conditions.
   
• Evidence indicates that Asia Pacific is among the fastest‑growing regions, driven by improvements in diagnostic capacity, growing clinical recognition of hyperammonemia‑related conditions, and wider adoption of advanced formulations like orally disintegrating tablets.
   
• Moreover, with the increase in patient access to new therapies from investments in therapeutic innovation and improved access via strengthened pharmaceutical supply chains throughout Asia Pacific, the uptake of therapeutic medication in the region will continue to rise, which in turn drives the continued growth in the carglumic acid market in the Asia Pacific region.
   

Latin America Carglumic Acid Market

The Latin American carglumic acid market is anticipated to exhibit remarkable growth during the analysis period.
 

• Growth in Latin America’s carglumic acid market is supported by increasing awareness of metabolic disorders and gradual expansion of access to rare‑disease therapies.
   
• Infrastructure improvements across the region are improving diagnostic capabilities and participating in multinational distribution and clinical networks, improving the access and distribution of specialty medications used to treat hyperammonemia and other metabolic disorders.
   
• Further, as healthcare systems continue advancing and metabolic disease recognition spreads, Latin America is expected to show steady, demand‑driven growth in carglumic acid utilization.
   

Middle East and Africa Carglumic Acid Market

The Middle East and Africa carglumic acid market is expected to experience substantial growth over the analysis timeframe.
 

• The Middle East & Africa region demonstrates increasing engagement in the carglumic acid market, supported by gradually improving healthcare infrastructure and growing awareness of rare metabolic disorders.
   
• The region is explicitly included among global markets utilizing orally disintegrating and suspension tablet formulations, indicating active therapeutic adoption within specialized treatment centers.
   
• Further, as diagnostic practices develop and access to metabolic‑care resources expands, particularly in Gulf countries and parts of North Africa, more patients receive targeted therapy for hyperammonemia conditions.
   

Carglumic Acid Market Share

The carglumic acid market features a competitive landscape and is consolidated due to the specialty nature of the drug (i.e., it is used to treat orphan or ultra-orphan diseases). There are only a few pharmaceutical companies that have sufficient experience, expertise, and capacity to manufacture this product.
 

Recordati Rare Diseases Inc. has an established history and experience with rare metabolic diseases. Therefore, they have a significant advantage related to regulatory compliance, consistent supply, and familiarity with clinical practices.
 

Similarly, Dipharma adds competition through their ability to manufacture using advanced API synthesis and a strong scientific foundation, which allows them to efficiently produce complex molecules. Their chemistry-based position allows them to service both captive and partner channels for formulations.
 

Additionally, through expanding API manufacturing capabilities and creating low-cost production models, as well as adhering to international quality standards, Apothecon Pharmaceuticals and Biophore India Pharmaceuticals have enhanced their competitive positions. Their commitment to producing hard-to-make molecules may allow both companies to diversify the global supply of these products.
 

Lastly, competition will be determined more by quality and regulatory strength, as well as through formulation expertise, rather than just volume, actively assisting clinicians and patients in the rare disease arena.
 

Carglumic Acid Market Companies

A few of the prominent players operating in the global carglumic acid industry include:

• Apothecon Pharmaceuticals
• Biophore India Pharmaceuticals
• Dipharma
• Eton Pharmaceuticals
• KAVYA PHARMA
• MANUS AKTTEVA BIOPHARMA
• Merck KGaA
• NOVITIUM PHARMA
• NURAY CHEMICALS
• Recordati Rare Diseases Inc.
• Suven Life Sciences
   
• Recordati Rare Diseases Inc.

Recordati can strengthen global reach by expanding patient‑support programs, enhancing physician education on rare metabolic disorders, investing in lifecycle management of existing therapies, and forming strategic partnerships to increase diagnostic access and treatment adoption.
 

• Dipharma

Dipharma can focus on advanced API manufacturing innovation, expand custom synthesis capabilities, strengthen regulatory compliance excellence, and deepen collaborations with biotech firms to accelerate development of high‑value niche molecules across global markets.
 

The global carglumic acid market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

By Dosage Form

• Orally disintegrating tablets
• Dispersible tablets
• Other dosage forms

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE